Experimental research on the development of new treatment strategies for triple negative breast cancer

我们用乳腺癌细胞株研究了聚腺苷二磷酸核糖聚合酶(PARP)1抑制剂olaparib和mTOR抑制剂evolimus(Eve)的抗肿瘤活性。考察了助剂对CSC比例的影响。奥拉帕利不仅对TNBC细胞具有生长抑制活性，而且对ER阳性、HER2阴性的细胞也具有生长抑制活性。奥拉帕利布与抗雌激素(AE)联合处理对ER阳性细胞系有相加的生长抑制作用。用一组不同亚型的人乳腺癌细胞系研究了EVE的抗肿瘤活性。EVE对BRCA1突变的TNBC细胞株有强烈的生长抑制作用，对部分ER阳性的乳腺癌细胞株也有中等的生长抑制作用。EVE有降低大多数细胞系CSC比例的趋势。

We conducted experimental studies to investigate anti-tumor activity of a poly-ADP-ribose polymerase (PARP) 1 inhibitor olaparib and a mTOR inhibitor everolimus (EVE) using breast cancer cell lines. We also investigated the effects of the agents on the ratio of CSC. Olaparib possesses growth inhibitory activity in not only TNBC cell lines but also ER-positive, HER2-negative cell lines. A combined treatment of olaparib with antiestrogen (AE) rendered an additive growth inhibitory effect in ER-positive cell lines. Anti-tumor activity of EVE was investigated using a panel of human breast cancer cell lines of various subtypes. EVE possessed a drastic growth inhibitory effect on a BRCA1-mutated, TNBC cell line and also exhibited a moderate growth inhibitory effect on a part of ER-positive breast cancer cells lines. EVE tended to decrease the ratio of CSC in most cell lines.